These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1440852)

  • 1. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.
    Anasetti C; Martin PJ; Storb R; Appelbaum FR; Beatty PG; Davis J; Doney K; Hill HF; Stewart P; Sullivan KM
    Transplantation; 1992 Nov; 54(5):844-51. PubMed ID: 1440852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies.
    Martin PJ; Hansen JA; Anasetti C; Zutter M; Durnam D; Storb R; Thomas ED
    Am J Kidney Dis; 1988 Feb; 11(2):149-52. PubMed ID: 3277406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient.
    Mysliwietz J; Thierfelder S
    Blood; 1992 Nov; 80(10):2661-7. PubMed ID: 1358260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.
    Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R
    Blood; 1994 Aug; 84(4):1320-7. PubMed ID: 8049447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease.
    Anasetti C; Martin PJ; Hansen JA; Appelbaum FR; Beatty PG; Doney K; Harkonen S; Jackson A; Reichert T; Stewart P
    Transplantation; 1990 Jul; 50(1):49-54. PubMed ID: 2368150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease.
    Remlinger K; Martin PJ; Hansen JA; Doney KC; Smith A; Deeg HJ; Sullivan K; Storb R; Thomas ED
    Hum Immunol; 1984 Jan; 9(1):21-35. PubMed ID: 6198309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
    Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
    Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
    Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
    Carpenter PA; Appelbaum FR; Corey L; Deeg HJ; Doney K; Gooley T; Krueger J; Martin P; Pavlovic S; Sanders J; Slattery J; Levitt D; Storb R; Woolfrey A; Anasetti C
    Blood; 2002 Apr; 99(8):2712-9. PubMed ID: 11929757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
    Norman DJ; Vincenti F; de Mattos AM; Barry JM; Levitt DJ; Wedel NI; Maia M; Light SE
    Transplantation; 2000 Dec; 70(12):1707-12. PubMed ID: 11152101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
    Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
    Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
    Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
    Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody.
    Zhang C; Lou J; Li N; Todorov I; Lin CL; Cao YA; Contag CH; Kandeel F; Forman S; Zeng D
    J Immunol; 2007 Jan; 178(2):838-50. PubMed ID: 17202345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
    Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor.
    Beelen DW; Grosse-Wilde H; Ryschka U; Quabeck K; Sayer HG; Graeven U; Schaefer UW
    Cancer Immunol Immunother; 1991; 34(2):97-102. PubMed ID: 1836976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
    van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
    Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.